158 related articles for article (PubMed ID: 8014066)
1. Circadian variation of 5-fluorouracil and cis-platinum toxicity in mice.
Shakil A; Hirabayashi N; Toge T
Hiroshima J Med Sci; 1993 Dec; 42(4):147-54. PubMed ID: 8014066
[TBL] [Abstract][Full Text] [Related]
2. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice.
Boughattas NA; Lévi F; Fournier C; Hecquet B; Lemaigre G; Roulon A; Mathé G; Reinberg A
J Pharmacol Exp Ther; 1990 Nov; 255(2):672-9. PubMed ID: 2243347
[TBL] [Abstract][Full Text] [Related]
3. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice.
Boughattas NA; Lévi F; Fournier C; Lemaigre G; Roulon A; Hecquet B; Mathé G; Reinberg A
Cancer Res; 1989 Jun; 49(12):3362-8. PubMed ID: 2720689
[TBL] [Abstract][Full Text] [Related]
4. Circadian rhythm and 5-fluorouracil toxicity in C3H mice.
Popovic P; Popovic V; Baughman J
Prog Clin Biol Res; 1982; 107():185-7. PubMed ID: 7167477
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel chronopharmacology in mice.
Tampellini M; Filipski E; Liu XH; Lemaigre G; Li XM; Vrignaud P; François E; Bissery MC; Lévi F
Cancer Res; 1998 Sep; 58(17):3896-904. PubMed ID: 9731500
[TBL] [Abstract][Full Text] [Related]
6. Circadian variations in myelosuppressive activity of interferon-alpha in mice: identification of an optimal treatment time associated with reduced myelosuppressive activity.
Koren S; Fleischmann WR
Exp Hematol; 1993 Apr; 21(4):552-9. PubMed ID: 8462664
[TBL] [Abstract][Full Text] [Related]
7. Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice.
Filipski E; Amat S; Lemaigre G; Vincenti M; Breillout F; Lévi FA
J Pharmacol Exp Ther; 1999 Apr; 289(1):231-5. PubMed ID: 10087009
[TBL] [Abstract][Full Text] [Related]
8. Circadian rhythm-modulated chemotherapy with high dose 5-fluorouracil against gastrointestinal cancers: evaluation and case report.
Kojima H; Sakamoto J; Yasue M
Nagoya J Med Sci; 1999 May; 62(1-2):29-38. PubMed ID: 10504825
[TBL] [Abstract][Full Text] [Related]
9. Dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats.
To H; Ohdo S; Shin M; Uchimaru H; Yukawa E; Higuchi S; Fujimura A; Kobayashi E
J Pharm Pharmacol; 2003 Jun; 55(6):803-10. PubMed ID: 12841941
[TBL] [Abstract][Full Text] [Related]
10. Modification of the bone marrow toxicity of cis-diamminedichloroplatinum(II) in mice by diethyldithiocarbamate.
Evans RG; Wheatley C; Engel C; Nielsen J; Ciborowski LJ
Cancer Res; 1984 Sep; 44(9):3686-90. PubMed ID: 6331656
[TBL] [Abstract][Full Text] [Related]
11. Influence of treatment sequence on efficacy of fluorouracil and cisplatin intratumoral drug delivery in vivo.
Yu NY; Patawaran MB; Chen JY; Orenberg EK; Brown DM; Luck EE
Cancer J Sci Am; 1995; 1(3):215-21. PubMed ID: 9166479
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of glutathione on 5-fluorouracil-induced myelosuppression in mice.
Kojima S; Takaba K; Kimoto N; Takeda T; Kakuni M; Mizutani M; Suzuki K; Sato H; Hara T
Arch Toxicol; 2003 May; 77(5):285-90. PubMed ID: 12734643
[TBL] [Abstract][Full Text] [Related]
13. Circadian time-dependent differences in murine tolerance to the antihistaminic agent loratadine.
Dridi D; Boughattas NA; Aouam K; Reinberg A; Ben Attia M
Chronobiol Int; 2005; 22(3):499-514. PubMed ID: 16076650
[TBL] [Abstract][Full Text] [Related]
14. Improved therapeutic index of cisplatin analogue: B-85-0040 by circadian timing.
von Roemeling R; Portuese E; Salzer M; Solis O; Bennett J; Sothern R; Hoffmann D; Sedlacek H
Prog Clin Biol Res; 1990; 341A():11-20. PubMed ID: 2217224
[TBL] [Abstract][Full Text] [Related]
15. Chronotoxicity of methotrexate in mice after intraperitoneal administration.
Labat C; Mansour K; Malmary MF; Terrissol M; Oustrin J
Chronobiologia; 1987; 14(3):267-75. PubMed ID: 3677924
[TBL] [Abstract][Full Text] [Related]
16. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
17. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
18. A somatostatin analogue (SMS 201-995) alters the toxicity of 5-fluorouracil in Swiss mice.
Lee JM; Erlich RB; Bruckner HW; Szrajer L; Ohnuma T
Anticancer Res; 1993; 13(5A):1453-6. PubMed ID: 8239519
[TBL] [Abstract][Full Text] [Related]
19. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
20. Circadian variations of bone marrow engraftability.
D'Hondt L; McAuliffe C; Damon J; Reilly J; Carlson J; Dooner M; Colvin G; Lambert JF; Hsieh CC; Habibian H; Stencel K; Quesenberry PJ
J Cell Physiol; 2004 Jul; 200(1):63-70. PubMed ID: 15137058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
